Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents

被引：0
|
作者：
Jean-Marc Barret
Anna Kruczynski
Chantal Etiévant
Bridget T. Hill
机构：
[1] Division de Cancérologie,
[2] Centre de Recherche Pierre Fabre,undefined
[3] 17 avenue Jean Moulin,undefined
[4] 81100 Castres,undefined
[5] France,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2002年 / 49卷
关键词：
F 11782 Combination index Synergy Cultured cells In vivo;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：479 / 486
页数：7
相关论文
共 50 条
  • [11] Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II
    Molinaro, Caroline
    Martoriati, Alain
    Pelinski, Lydie
    Cailliau, Katia
    CANCERS, 2020, 12 (10) : 1 - 26
  • [12] Oracine a novel inhibitor of topoisomerases I and II
    Miko, M
    Turna, J
    Stuchlík, S
    Soucek, R
    12TH MEDITERRANEAN CONGRESS OF CHEMOTHERAPY, 2000, : 331 - 336
  • [13] F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103
    Etiévant, C
    Kruczynski, A
    Barret, JM
    Perrin, D
    van Hille, B
    Guminski, Y
    Hill, BT
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 46 (02) : 101 - 113
  • [14] F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103
    Chantal Etiévant
    Anna Kruczynski
    Jean-Marc Barret
    Dominique Perrin
    Benoît van Hille
    Yves Guminski
    Bridget T. Hill
    Cancer Chemotherapy and Pharmacology, 2000, 46 : 101 - 113
  • [15] F 11782, a novel catalytic inhibitor of topoisomerases I and II, induces atypical, yet cytotoxic DNA double-strand breaks in CHO-K1 cells
    Barret, JM
    Etiévant, C
    Baudouin, C
    Skov, K
    Charvéron, M
    Hill, BT
    ANTICANCER RESEARCH, 2002, 22 (1A) : 187 - 192
  • [16] Decreased nucleotide excision repair activity and alterations of topoisomerase IIα are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II
    Kruczynski, A
    Barret, JM
    van Hille, B
    Chansard, N
    Astruc, J
    Menon, Y
    Duchier, C
    Créancier, L
    Hill, BT
    CLINICAL CANCER RESEARCH, 2004, 10 (09) : 3156 - 3168
  • [17] F11782, a novel dual topoisomerase I and II inhibitor exhibits significant in vitro activity against fresh cells from haematological malignancies
    Sargent, JM
    Elgie, AW
    Williamson, CJ
    Taylor, C
    Hill, BT
    LEUKEMIA, 2001, 15 (03) : 507 - 507
  • [18] In vitro and in vivo synergistic effects of F14512, a novel targeted cytotoxic agent in phase I clinical study, in combination with other anticancer drugs
    Vandenberghe, Isabelle
    Annereau, Jean-Philippe
    Brel, Viviane
    Vispe, Stephane
    Barret, Jean-Marc
    Gomes, Bruno
    Offrete, Vanessa
    Andre, Karine
    Roy, Sabine
    Castano, Caroline
    Celestin, Fiona
    Guminski, Yves
    Imbert, Thierry
    Kruczynski, Anna
    Guilbaud, Nicolas
    Bailly, Christian
    CANCER RESEARCH, 2011, 71
  • [19] In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs
    Jean-Marc Barret
    Chantal Etiévant
    Bridget T. Hill
    Cancer Chemotherapy and Pharmacology, 2000, 45 : 471 - 476
  • [20] In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs
    Barret, JM
    Etiévant, C
    Hill, BT
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 45 (06) : 471 - 476
12345